drugset / Trial / NCT03821987
Risk Stratification Directed Conditioning Regimen for Haploidentical HSCT in SAA
NaSingle-groupOpen-labelTreatment
Summary
The haplotype HSCT system including Bu(0.8mg/kg Q6hx2d)CTX(50mg/kgx4d)rATG(2.5mg/kgx4d) , established in Institute of Hematology of Peking University ,has been evaluated to be effective for acquired SAA.But some patients with high risk factors may not tolerate CTX 200mg/kg,alternative conditioning regimen including Bu/Fludarabine/dercreased CTX was studied in this trial.
Timeline
- Start
- 2018-12-17
- Primary completion
- 2021-12-30
- Completion
- 2022-03-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Busulfan | Small molecule | 0.8 mg/kg | Intravenous |
| Subject | Cyclophosphamide | Other / unclassified | 25 mg/kg | — |
| Subject | Fludarabine | Small molecule | 30 mg/m2 | — |
| Subject | Thymoglobulin | Protein / enzyme biologic | 2.5 mg/kg | — |